Published in Thromb Haemost on April 30, 1986
Transforming growth factor-beta is a strong and fast acting positive regulator of the level of type-1 plasminogen activator inhibitor mRNA in WI-38 human lung fibroblasts. EMBO J (1987) 1.98
Lysosomal degradation of receptor-bound urokinase-type plasminogen activator is enhanced by its inhibitors in human trophoblastic choriocarcinoma cells. Cell Regul (1990) 1.06
Plasminogen activator inhibitor type 1 biosynthesis and mRNA level are increased by dexamethasone in human fibrosarcoma cells. Mol Cell Biol (1987) 0.96
Functional stability of plasminogen activator inhibitor-1. ScientificWorldJournal (2014) 0.87
Task shifting in HIV/AIDS: opportunities, challenges and proposed actions for sub-Saharan Africa. Trans R Soc Trop Med Hyg (2008) 6.39
Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res (1997) 2.98
Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab (2003) 2.41
Reduced tuberculosis case notification associated with scaling up antiretroviral treatment in rural Malawi. Int J Tuberc Lung Dis (2011) 2.13
Nonsense suppressors of Saccharomyces cerevisiae can be generated by mutation of the tyrosine tRNA anticodon. Nature (1976) 2.07
Biosynthesis of the beta and beta' subunits of RNA polymerase in Escherichia coli. J Mol Biol (1973) 2.03
Properties of the K562 cell line, derived from a patient with chronic myeloid leukemia. Int J Cancer (1976) 1.97
Replication of the F'lac sex factor in the cell cycle of Escherichia coli. Mol Gen Genet (1971) 1.92
Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chromatography with monoclonal antibody. Biochemistry (1982) 1.85
Neutrophil adherence to endothelium is enhanced via adenosine A1 receptors and inhibited via adenosine A2 receptors. J Immunol (1992) 1.84
Somatic mutation of the Peutz-Jeghers syndrome gene, LKB1/STK11, in malignant melanoma. Oncogene (1999) 1.59
The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res (1996) 1.55
Differences in the binding to fibrin of native plasminogen and plasminogen modified by proteolytic degradation. Influence of omega-aminocarboxylic acids. Biochim Biophys Acta (1975) 1.53
Hybridization of a myeloid leukemia-derived human cell line (K562) with a human Burkitt's lymphoma line (P3HR-1). J Natl Cancer Inst (1980) 1.53
Real-time RT-PCR detection of disseminated tumour cells in bone marrow has superior prognostic significance in comparison with circulating tumour cells in patients with breast cancer. Br J Cancer (2006) 1.46
Inducibility of the Epstein-Barr virus (EBV) cycle and surface marker properties of EBV-negative lymphoma lines and their in vitro EBV-converted sublines. Int J Cancer (1976) 1.41
Somatic Fas mutations in non-Hodgkin's lymphoma: association with extranodal disease and autoimmunity. Blood (1998) 1.41
Initial plasmin-degradation of fibrin as the basis of a positive feed-back mechanism in fibrinolysis. Eur J Biochem (1984) 1.40
Biological background subtraction improves immunoscintigraphy by subsequent injection of antigen. J Nucl Med (1991) 1.39
Higher-order structure of human mitotic chromosomes. Proc Natl Acad Sci U S A (1977) 1.38
Isolation of novel HLA-DR restricted potential tumor-associated antigens from the melanoma cell line FM3. Cancer Res (1997) 1.38
Increased levels of plasma anaphylatoxins in systemic lupus erythematosus predict flares of the disease and may elicit vascular injury in lupus cerebritis. Arthritis Rheum (1988) 1.34
Adsorption to fibrin of native fragments of known primary structure from human plasminogen. Biochim Biophys Acta (1981) 1.32
Identification of an Epstein-Barr virus-coded thymidine kinase. EMBO J (1986) 1.31
Differences in the binding to fibrin of urokinase and tissue plasminogen activator. Thromb Diath Haemorrh (1972) 1.31
Alterations of the MMAC1/PTEN gene in lymphoid malignancies. Blood (1998) 1.27
Accumulation of identical T cells in melanoma and vitiligo-like leukoderma. J Invest Dermatol (1999) 1.24
Characterization of a human ovarian teratocarcinoma-derived cell line. Int J Cancer (1980) 1.19
Phosphorylated peptides can be transported by TAP molecules, presented by class I MHC molecules, and recognized by phosphopeptide-specific CTL. J Immunol (1999) 1.19
Fatal endocarditis due to Aerococcus urinae. Diagn Microbiol Infect Dis (1995) 1.16
Human endothelial cells produce a plasminogen activator inhibitor and a tissue-type plasminogen activator-inhibitor complex. Biochim Biophys Acta (1984) 1.15
Plasminogen and tissue-type plasminogen activator bind to immobilized fibronectin. J Biol Chem (1985) 1.15
Tumour-specific MHC-class-II-restricted responses after in vitro sensitization to synthetic peptides corresponding to gp100 and Annexin II eluted from melanoma cells. Cancer Immunol Immunother (1998) 1.15
Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide. Proc Natl Acad Sci U S A (1996) 1.14
Mutation and allelic loss of the PTEN/MMAC1 gene in primary and metastatic melanoma biopsies. J Invest Dermatol (2000) 1.12
Fibrinogenolysis and fibrinolysis with tissue plasminogen activator, urokinase, streptokinase-activated human globulin, and plasmin. Proc Soc Exp Biol Med (1971) 1.12
Single-step DGGE-based mutation scanning of the p53 gene: application to genetic diagnosis of colorectal cancer. Hum Mutat (1997) 1.09
Transformation induced by Epstein-Barr virus and the role of the nuclear antigen. Cold Spring Harb Symp Quant Biol (1980) 1.08
Properties of three different molecular forms of the alpha 2 plasmin inhibitor. Eur J Biochem (1981) 1.08
Out-of-pocket costs of AIDS care in China: are free antiretroviral drugs enough? AIDS Care (2008) 1.06
Isolation of tissue-type plasminogen activator-inhibitor complexes from human plasma. Evidence for a rapid plasminogen activator inhibitor. Biochim Biophys Acta (1984) 1.06
HLA antigen expression at the single cell level on a K562 X B cell hybrid: an analysis with monoclonal antibodies using bacterial binding assays. Somatic Cell Genet (1982) 1.06
Secondary-site binding of Glu-plasmin, Lys-plasmin and miniplasmin to fibrin. Biochem J (1981) 1.06
Antiretroviral therapy for HIV prevention: many concerns and challenges, but are there ways forward in sub-Saharan Africa? Trans R Soc Trop Med Hyg (2010) 1.05
Presentation of cytosolic glycosylated peptides by human class I major histocompatibility complex molecules in vivo. J Exp Med (1999) 1.05
Foci of Schistosomiasis mekongi, Northern Cambodia: II. Distribution of infection and morbidity. Trop Med Int Health (1999) 1.04
Inactive proenzyme to tissue-type plasminogen activator from human melanoma cells, identified after affinity purification with a monoclonal antibody. EMBO J (1984) 1.03
In situ T cells in melanoma. Cancer Immunol Immunother (1999) 1.01
Two-site time-resolved immunofluorometric assay of human insulin. Clin Chem (1986) 1.01
Ecto-ATP diphosphohydrolase/CD39 is overexpressed in differentiated human melanomas. FEBS Lett (1998) 1.01
Poor correspondence between predicted and experimental binding of peptides to class I MHC molecules. Tissue Antigens (2000) 1.00
Monoclonal antibody to human 66,000 molecular weight plasminogen activator from melanoma cells. Specific enzyme inhibition and one-step affinity purification. EMBO J (1983) 0.99
Expression of basic fibroblast growth factor and vascular endothelial growth factor in primary and metastatic melanoma from the same patients. Melanoma Res (1999) 0.98
Detection and characterization of alpha-beta-T-cell clonality by denaturing gradient gel electrophoresis (DGGE). Biotechniques (1998) 0.97
Monoclonal antibody that specifically inhibits a human Mr 52,000 plasminogen-activating enzyme. Proc Natl Acad Sci U S A (1982) 0.97
Symptomatic infection with Blastocystis sp. subtype 8 successfully treated with trimethoprim-sulfamethoxazole. Ann Trop Med Parasitol (2008) 0.96
Multiple mechanisms of immune evasion can coexist in melanoma tumor cell lines derived from the same patient. Cancer Immunol Immunother (2001) 0.96
Somatic cell hybrids between human lymphoma lines. III. Surface markers. Int J Cancer (1977) 0.96
Enzyme-linked immunosorbent assay for human urokinase-type plasminogen activator and its proenzyme using a combination of monoclonal and polyclonal antibodies. J Immunoassay (1986) 0.96
In situ T cell responses against melanoma comprise high numbers of locally expanded T cell clonotypes. J Immunol (1999) 0.96
Monoclonal antibodies to K88ab, K88ac and K88ad fimbriae from enterotoxigenic Escherichia coli. Microb Pathog (1986) 0.95
Effect of intravenous N-acetylcysteine infusion on haemostatic parameters in healthy subjects. Gut (2005) 0.95
An essential arginyl residue in yeast hexokinase. Biochim Biophys Acta (1979) 0.95
The V410I (G1228A) variant of the caspase-10 gene is a common polymorphism of the Danish population. Blood (2000) 0.95
Human-human hybridomas and human monoclonal antibodies obtained by fusion of lymph node lymphocytes from breast cancer patients. Cancer Res (1988) 0.95
Different N-terminal forms of alpha 2-plasmin inhibitor in human plasma. Biochem J (1993) 0.94
Clonal T cell responses in tumor infiltrating lymphocytes from both regressive and progressive regions of primary human malignant melanoma. J Clin Invest (1996) 0.94
Rate of activation and electrophoretic mobility of unmodified and partially degraded plasminogen. Effects of 6-aminohexanoic acid and related compounds. Scand J Clin Lab Invest (1974) 0.94
Inhibition of neutrophil function by aspirin-like drugs (NSAIDS): requirement for assembly of heterotrimeric G proteins in bilayer phospholipid. Biochem Pharmacol (1994) 0.93
Cell cycle arrest by the PTEN tumor suppressor is target cell specific and may require protein phosphatase activity. Exp Cell Res (2000) 0.92
Activation of preexisting T cell clones by targeted interleukin 2 therapy. Proc Natl Acad Sci U S A (1998) 0.92
Regulation of B lymphocyte replication and maturation. J Cell Biochem (1982) 0.92
Pattern of replication of a colicin factor during the cell cycle of Escherichia coli. J Bacteriol (1972) 0.91
Somatic cell hybrids between human lymphoma lines. IV. Establishment and characterization of a P3HR-1/Daudi hybrid. Int J Cancer (1978) 0.91
Aberrant p27Kip1 promoter methylation in malignant melanoma. Oncogene (2000) 0.91
Plasminogen activating enzyme in cultured glioblastoma cells. An immunofluorescence study with monoclonal antibody. J Histochem Cytochem (1982) 0.90
Melanoma-associated antigens recognized by cytotoxic T lymphocytes. APMIS (1998) 0.90
Expression of transporter associated with antigen processing 1 and 2 (TAP1/2) in malignant melanoma cell lines. Int J Cancer (1997) 0.89
The selection of somatic cell hybrids between human lymphoma cell lines. Somatic Cell Genet (1976) 0.89
Reactivation of chick erythrocyte nuclei after fusion with enucleated cells. Somatic Cell Genet (1975) 0.89
Kinetics of inhibition of tissue-type and urokinase-type plasminogen activator by plasminogen-activator inhibitor type 1 and type 2. Eur J Biochem (1988) 0.89
Epstein-Barr virus (EBV), lymphocytes and transformation. J Cancer Res Clin Oncol (1983) 0.89
Somatic cell hybrids between human lymphoma lines. II. Spontaneous and induced patterns of the Epstein-Barr virus (EBV) cycle. Int J Cancer (1976) 0.89
Escape from host-antitumor immunity. Crit Rev Oncog (1997) 0.88
The physiology of fibrinolysis. Med Clin North Am (1972) 0.88
Outside-in signaling in the chondrocyte. Nitric oxide disrupts fibronectin-induced assembly of a subplasmalemmal actin/rho A/focal adhesion kinase signaling complex. J Clin Invest (1997) 0.87
An assay for peptide binding to HLA-Cw*0102. Tissue Antigens (1999) 0.87
Reversible and irreversible alterations of human plasminogen indicated by changes in susceptibility to plasminogen activators and in response to epsilon-aminocaproic acid. Thromb Diath Haemorrh (1974) 0.87
Transfection of glioma cells with the neural-cell adhesion molecule NCAM: effect on glioma-cell invasion and growth in vivo. Int J Cancer (1994) 0.86
Higher-order structure of mitotic chromosomes. Cold Spring Harb Symp Quant Biol (1978) 0.86
Sequence of formation of molecular forms of plasminogen and plasmin-inhibitor complexes in plasma activated by urokinase or tissue-type plasminogen activator. Biochem J (1984) 0.86
Human urokinase and porcine tissue plasminogen activator. A comparative study of the mechanism of fibrinolysis, and the effect of natural proteinase inhibitors and omega-aminocarboxylic acids. Dan Med Bull (1977) 0.86
Expression of immunoglobulin synthesis in human myeloma x non-lymphoid cell heterokaryons: evidence for negative control. Cell Differ (1976) 0.86
Preferential usage of T-cell receptor alpha beta variable regions among tumor-infiltrating lymphocytes in primary human malignant melanomas. Int J Cancer (1994) 0.86
The inhibition of tissue plasminogen activator and urokinase-induced fibrinolysis by some natural proteinase inhibitors and by plasma and serum from normal and pregnant subjects. Scand J Clin Lab Invest (1973) 0.86
A one-step DGGE scanning method for detection of mutations in the K-, N-, and H-ras oncogenes: mutations at codons 12, 13 and 61 are rare in B-cell non-Hodgkin's lymphoma. Int J Cancer (1997) 0.86